| 摘要 |
8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-[4.3.0]nonan-8-yl)-6-f luoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid (CCDC) of the crystal modification C, characterised in that it has an X-ray powder diffractogram with the following reflection signals (2 theta) of high and medium intensity: 5.7, 12.6, 15.5, 17.2, 20.2, 26.4, 27. CCDC of the modification C is used to prepared medicaments. Also described is the use of CCDC of the modification C for the treatment or prophylaxis of bacterial conditions in non-human animals.
|
